Publication
Chemoradiotherapy versus short-course radiotherapy for response-adapted organ preservation in early-stage and intermediate-stage rectal cancer (STAR-TREC): 12-month results of an international, multicentre, open-label, parallel-group, randomised, phase 2/3 trial.
Simon P Bach, David Sebag-Montefiore, Victoria Homer, Alexandra Gilbert, Ane Appelt, Ian Geh, Geerard L Beets, Jacobus Burger, Eva Angenete, Gunnar Baatrup, Karen-Lise Garm Spindler, Karin Haustermans, Fabian Holman, Ellen M Kerkhof, Emily Lam, Stephan Korsgen, Anna Martling, Albert Wolthuis, Issam Al-Najami, Pehr Lind, Femke P Peters, Mark Teo, Nicholas P West, Simon Gates, Corrie A M Marijnen, Johannes H W de Wilt, STAR-TREC Collaborative
- Source
- PubMed
- Retrieved
- Sep 10, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-PUBMED-20260910-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
BACKGROUND: Total mesorectal excision (TME) is the standard treatment for most early-stage and intermediate-stage rectal cancer but can cause substantial perioperative morbidity, functional impairment, and reduced quality of life. We assessed whether long-course chemoradiotherapy (LCCRT) or…
Read on PubMedLinked entities
Linked entities (1)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Candidate 1
- cancerMalignant Rectal Neoplasmdictionary0.60
Curated evidence
Evidence citing this paper (0)
Data not yet available